During Merck & Co. Inc. Merck & Co. Inc.’s Nov. 10 analyst meeting, Roger Pomerantz, it head of infectious diseases, talked about the progress of Merck’s hepatitis C franchise.
Pomerantz, who joined Merck in 2010 from Johnson & Johnson’s Tibotec, has been named the new head of Merck’s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?